HK1203206A1 - 抗體及其應用 - Google Patents
抗體及其應用Info
- Publication number
- HK1203206A1 HK1203206A1 HK15103635.8A HK15103635A HK1203206A1 HK 1203206 A1 HK1203206 A1 HK 1203206A1 HK 15103635 A HK15103635 A HK 15103635A HK 1203206 A1 HK1203206 A1 HK 1203206A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007280187 | 2007-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203206A1 true HK1203206A1 (zh) | 2015-10-23 |
Family
ID=40591051
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11104163.0A HK1150061A1 (zh) | 2007-10-29 | 2011-04-26 | 抗體及其應用 |
HK15103635.8A HK1203206A1 (zh) | 2007-10-29 | 2015-04-14 | 抗體及其應用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11104163.0A HK1150061A1 (zh) | 2007-10-29 | 2011-04-26 | 抗體及其應用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8445649B2 (zh) |
EP (1) | EP2224000B1 (zh) |
JP (3) | JP5185946B2 (zh) |
CN (2) | CN104098695B (zh) |
HK (2) | HK1150061A1 (zh) |
WO (1) | WO2009057664A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8987419B2 (en) * | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2012104824A1 (en) * | 2011-02-04 | 2012-08-09 | Ecole polytechnique fédérale de Lausanne (EPFL) | Therapeutic antibodies targeting app-c99 |
AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
WO2013094614A1 (ja) | 2011-12-22 | 2013-06-27 | Taoヘルスライフファーマ株式会社 | 合成アミロスフェロイドの製造方法 |
JP2019038806A (ja) * | 2011-12-29 | 2019-03-14 | Taoヘルスライフファーマ株式会社 | アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用 |
KR20140068105A (ko) * | 2011-12-29 | 2014-06-05 | 타오 헬스 라이프 파마 가부시키가이샤 | 아밀로스페로이드가 결합하여 성숙 신경 세포사를 유발하는 표적 분자, 아밀로스페로이드가 유도하는 신경 세포사를 억제하는 방법 및 물질, 및 그들의 이용 |
BR112015008347B1 (pt) * | 2012-10-15 | 2023-12-26 | Medimmune Limited | Molécula de anticorpo, uso de dita molécula de anticorpo, composição para uso no tratamento de uma doença associada com betaamilóide, uso de uma composição, ácido nucleico, célula hospedeira e método para produção de uma molécula de anticorpo |
JP6582995B2 (ja) * | 2014-01-21 | 2019-10-02 | 株式会社島津製作所 | App切断型ペプチドの測定方法 |
KR20180134373A (ko) * | 2016-04-14 | 2018-12-18 | 타오 헬스 라이프 파마 가부시키가이샤 | 아밀로스페로이드(aspd)형 구조체 및 의약 조성물 |
EP4062929A4 (en) * | 2019-11-19 | 2024-03-13 | Foundation For Biomedical Res And Innovation At Kobe | CROSS-LINKED PRODUCT OF AMYLOID-SS PROTEIN (A-SS). WHICH CAN BE A SUBSTITUTE FOR AMYLOSPHOID (ASPD), AND ANALYSIS OF ASPD |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
WO1990012871A1 (en) * | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
JP4227275B2 (ja) * | 2000-03-09 | 2009-02-18 | 三菱化学株式会社 | 高い毒性を有するアミロイドβ蛋白質の調製方法 |
JP4317317B2 (ja) * | 2000-09-28 | 2009-08-19 | 三菱化学株式会社 | 自己会合型アミロイドβ蛋白質 |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
ES2318006T3 (es) | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
CA2501091A1 (en) * | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
CN1849139A (zh) * | 2002-10-09 | 2006-10-18 | 里纳特神经系统学公司 | 使用针对淀粉样β肽的抗体及其组合物治疗阿尔茨海默氏病的方法 |
AT413945B (de) * | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
WO2006016644A1 (ja) * | 2004-08-11 | 2006-02-16 | Mitsubishi Chemical Corporation | 抗体及びその利用 |
JPWO2006046644A1 (ja) * | 2004-10-28 | 2008-05-22 | 三光純薬株式会社 | アルツハイマー病の検定方法及び診断試薬 |
CN101555477B (zh) * | 2009-04-22 | 2011-04-20 | 北京交通大学 | 抗人淀粉样蛋白单克隆抗体重轻链可变区基因及其应用 |
-
2008
- 2008-10-29 CN CN201410347530.3A patent/CN104098695B/zh active Active
- 2008-10-29 EP EP08844261.1A patent/EP2224000B1/en active Active
- 2008-10-29 CN CN200880113862.8A patent/CN101878301B/zh not_active Expired - Fee Related
- 2008-10-29 WO PCT/JP2008/069696 patent/WO2009057664A1/ja active Application Filing
- 2008-10-29 US US12/734,359 patent/US8445649B2/en active Active
- 2008-10-29 JP JP2009539096A patent/JP5185946B2/ja active Active
-
2011
- 2011-04-26 HK HK11104163.0A patent/HK1150061A1/zh not_active IP Right Cessation
-
2012
- 2012-12-11 JP JP2012270745A patent/JP2013135667A/ja active Pending
-
2015
- 2015-04-14 HK HK15103635.8A patent/HK1203206A1/zh not_active IP Right Cessation
- 2015-05-26 JP JP2015106830A patent/JP6128535B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2224000A4 (en) | 2012-06-27 |
JP6128535B2 (ja) | 2017-05-17 |
EP2224000A1 (en) | 2010-09-01 |
CN104098695A (zh) | 2014-10-15 |
CN104098695B (zh) | 2018-09-07 |
WO2009057664A1 (ja) | 2009-05-07 |
US20100297662A1 (en) | 2010-11-25 |
JP2015221796A (ja) | 2015-12-10 |
HK1150061A1 (zh) | 2011-10-28 |
JPWO2009057664A1 (ja) | 2011-03-10 |
JP2013135667A (ja) | 2013-07-11 |
EP2224000B1 (en) | 2020-05-13 |
CN101878301A (zh) | 2010-11-03 |
US8445649B2 (en) | 2013-05-21 |
CN101878301B (zh) | 2014-08-20 |
JP5185946B2 (ja) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180596T1 (hr) | PROTUTIJELA PROTIV Sp35 I NJIHOVA UPOTREBA | |
EP2236604A4 (en) | ANTI-NR10 ANTIBODIES AND USE THEREOF | |
SI2099826T1 (sl) | Anti-beta-amiloidno protitelo in njegova uporaba | |
HK1142341A1 (en) | Anti-hepcidin antibodies and uses thereof | |
IL200012A0 (en) | Anti-robo4 antibodies and uses therefor | |
ZA200900351B (en) | Prlr-specific antibody and uses thereof | |
ZA200810311B (en) | Anti-NKG2A antibodies and uses thereof | |
IL209309A0 (en) | Anti-fn14 antibodies and uses thereof | |
IL216731A (en) | And antibodies against p95 – her2 and their uses | |
EP2354161A4 (en) | ANTI-NR10 ANTIBODIES AND CORRESPONDING USE | |
HK1203206A1 (zh) | 抗體及其應用 | |
IL201034A0 (en) | Novel human anti-r7v antibodies and uses thereof | |
SI2354161T1 (sl) | Anti-NR10 protitelo in njegova uporaba | |
EP2388320A4 (en) | ANTI-HS6ST2 ANTIBODIES AND USE THEREOF | |
EP2128249A4 (en) | ZINC OXIDE FIXING ANTIBODIES AND USE THEREOF | |
EP2322610A4 (en) | ANTI-CLCP1 HUMAN ANTIBODIES AND USE THEREOF | |
EP2133326A4 (en) | NEW PSEUDOGLYCOLIPID AND ITS USE | |
GB0812277D0 (en) | Antibody and uses thereof | |
ZA200905136B (en) | Anti-robo4 antibodies and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20221101 |